Gene-editing holds substantial promise for treating thousands of diseases.
In fact, it could help treat the 7,000 diseases caused by genetic disorders, most of which occur with gene mutation. It could even help create a potential $29.93 billion market by 2032 from today’s $6.94 billion valuation, as noted by Precedence Research.
|
Company: CRISPR Therapeutics (SYM: CRSP) Look at CRISPR Therapeutics (SYM: CRSP), for example. |
TradeAlgo
It’s me, Jack Harris.
It is a worst-kept secret that Wall Street has been using artificial intelligence to dominate the trading business.
Sure enough…
I spotted this headline above during my daily news reading and it’s just one example of how Wall Street is using AI.
It’s time for retail traders like you to start using AI to level the playing field.
Click here to claim your FREE copy exclusively for Behind the Markets readers.
|
Company: Intellia Therapeutics (SYM: NTLA) Just weeks ago, the company reported positive long-term data from a Phase 1 study of NTLA-2002 for the treatment of hereditary angioedema (HAE), which impacts one in 50,000 people. According to the company, a single dose led to a 98% mean reduction in the “the monthly attack rate, with an average follow-up of over 20 months across all patients. It added that eight out of ten patients were completely attack-free following a 16-week primary observation period through the last follow-up, including patients with the most severe disease.” |
Oxford Club
Biggest Investors in the World LOADING UP on This AI Stock
It’s a small cap that trades for less than $10… Yet the biggest investors in the world own millions of shares.
Why? Because their AI just did something no company has ever done before.
Details here.
|
Company: Beam Therapeutics (SYM: BEAM) There’s Beam Therapeutics (SYM: BEAM), which develops BEAM-101 for sickle cell and beta-thalassemia; BEAM-302 for the treatment of severe alpha-1 antitrypsin deficiency; and BEAM-201 for refractory T-cell acute lymphoblastic leukemia / T-cell lymphoblastic lymphoma. Helping, analysts at H.C. Wainwright just initiated a buy rating on the BEAM stock with an $80 price target. The firm highlighted BEAM’s base editing as a key catalyst. |
